CPA
FOLD

Capital Performance Advisors’s Amicus Therapeutics FOLD Stock Holding History

Capital Performance Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-43
Closed -$459 – 1068
2024
Q3 		$459 Buy
+43
New +$468 ﹤0.01% 2292

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Performance Advisors's FOLD Position: Q4 2024 in Review

Capital Performance Advisors sold out of Amicus Therapeutics (FOLD) in Q4 2024, closing a stake of 43 shares — an estimated $459 sold.

Capital Performance Advisors first reported a position in FOLD in Q3 2024 and held it in 1 quarter. The position peaked at $459 in Q3 2024. 290 funds tracked by Wall St. Rank hold FOLD as of Q4 2024.

  • Capital Performance Advisors reported no remaining Amicus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 43 Amicus Therapeutics shares in Q4 2024, an estimated $459.
  • Capital Performance Advisors first reported a position in Amicus Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Amicus Therapeutics position peaked at $459 in Q3 2024.
  • 290 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.